Clinical Scorecard: Evaluating the Prognostic Significance of Initial PSMA PET/CT Imaging for Survival Outcomes in Synchronous Metastatic Hormone-Sensitive Prostate Cancer: A Shift in Understanding Low- versus High-Volume Disease

At a Glance

Key Highlights

• PSMA PET/CT improves sensitivity and specificity in detecting metastases compared to conventional imaging.

• Approximately 40% of patients with mHSPC are restaged due to PSMA PET/CT findings.

• Current LVD/HVD classification may be inadequate for treatment decisions based on PSMA PET/CT results.

• Incorporation of clinical prognostic variables alongside PSMA PET/CT findings is necessary for optimal treatment selection.

• The study aims to develop a prediction tool for personalized treatment decisions in mHSPC.

Guideline-Based Recommendations

Diagnosis

• Use PSMA PET/CT as the standard imaging modality for staging mHSPC.

Management

• Consider treatment intensification strategies based on PSMA PET/CT findings.

Monitoring & Follow-up

• Assess overall survival and PSA progression-free survival as key endpoints.

Risks

• Potential misclassification of disease burden if relying solely on LVD/HVD criteria.

Patient & Prescribing Data

Patients diagnosed with mHSPC at Leiden University Medical Centre or Alrijne Hospital.

ADT remains the backbone of treatment, with potential for intensification based on imaging findings.

Clinical Best Practices

• Incorporate PSMA PET/CT findings into treatment decision-making.

• Utilize multidisciplinary team meetings for reviewing imaging results and treatment planning.

• Regularly update risk stratification criteria to reflect advancements in imaging technology.

Related Resources & Content

1. Holzgreve et al, JAMA Network Open, 2023 -- Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases

2. European Radiology, 2023 -- Exploring the Role of PSMA-PET/CT and Whole-Body MRI in the Management of Advanced Prostate Cancer

3. European Radiology, 2023 -- Initial PSMA PET/CT Metrics as Predictors of Overall Survival and Treatment Efficacy in Patients with Metastatic Castration-Resistant Prostate Cancer

4. The ASCO Post, 2020 -- PSMA PET/CT May Have Major Impact on Treatment of Patients With Prostate Cancer

5. EAU Guidelines on Prostate Cancer, 2024 -- PSMA PET/CT

6. 5.8.3.3 **PSMA PET/CT**

7. Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. | Journal of Clinical Oncology

8. Diagnostic Evaluation - EAU Guidelines on Prostate Cancer - Uroweb